Who Paid My Doc
Elzonris
Drug Oncology
NDC 72187-0401-1
General payments
$1,834,244
Research payments
$6,275,120
Through program year 2025, $1,834,244 in general payments and $6,275,120 in research payments were reported against Elzonris (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $258,347 | 736 |
| 2025 | Research | $4,081,649 | 1,594 |
| 2024 | General | $396,973 | 696 |
| 2024 | Research | $251,842 | 44 |
| 2023 | General | $70,229 | 284 |
| 2022 | General | $344,449 | 502 |
| 2022 | Research | $1,941,628 | 65 |
| 2021 | General | $214,020 | 533 |
| 2020 | General | $276,189 | 617 |
| 2019 | General | $274,038 | 919 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 37 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 40 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,287 general · 1,703 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.